Hiroaki Ikeda

14.2k total citations · 3 hit papers
150 papers, 10.4k citations indexed

About

Hiroaki Ikeda is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Hiroaki Ikeda has authored 150 papers receiving a total of 10.4k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Immunology, 52 papers in Oncology and 45 papers in Molecular Biology. Recurrent topics in Hiroaki Ikeda's work include Immunotherapy and Immune Responses (58 papers), CAR-T cell therapy research (32 papers) and Immune Cell Function and Interaction (27 papers). Hiroaki Ikeda is often cited by papers focused on Immunotherapy and Immune Responses (58 papers), CAR-T cell therapy research (32 papers) and Immune Cell Function and Interaction (27 papers). Hiroaki Ikeda collaborates with scholars based in Japan, United States and France. Hiroaki Ikeda's co-authors include Lloyd J. Old, Robert D. Schreiber, Allen T. Bruce, Gavin P. Dunn, J. Michael White, Vijay Shankaran, Paul E. Swanson, Hiroshi Shiku, Takashi Nishimura and Isao Tawara and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Hiroaki Ikeda

139 papers receiving 10.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer immunoediting: from immunosurveillance to tumor escape

2002 3.7k citations Allen T. Bruce, Hiroaki Ikeda et al. profile →
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

2001 2.1k citations Vijay Shankaran, Hiroaki Ikeda et al. Nature profile →
The roles of IFNγ in protection against tumor development and cancer immunoediting

2002 724 citations Hiroaki Ikeda, Lloyd J. Old et al. profile →

Peers

Countries citing papers authored by Hiroaki Ikeda

Since Specialization

Citations

This map shows the geographic impact of Hiroaki Ikeda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroaki Ikeda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroaki Ikeda more than expected).

Fields of papers citing papers by Hiroaki Ikeda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroaki Ikeda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroaki Ikeda. The network helps show where Hiroaki Ikeda may publish in the future.

Co-authorship network of co-authors of Hiroaki Ikeda

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroaki Ikeda. A scholar is included among the top collaborators of Hiroaki Ikeda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroaki Ikeda. Hiroaki Ikeda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cancer immunotherapy in progress—an overview of the past 130 years 2025 ·International Immunology ·Hiroaki Ikeda	7
2	Low-frequency CD8+ T cells induced by SIGN-R1+ macrophage-targeted vaccine confer SARS-CoV-2 clearance in mice 2024 ·npj Vaccines ·(unknown), Meng Ling Moi, (unknown), (unknown), (unknown), (unknown), Rui Yamaguchi, Shin‐ichi Sawada, (unknown), (unknown), Yasunari Haseda, Takatoshi Soga, Hirokazu Matsushita, Hiroaki Ikeda, Kazunari Akiyoshi, Naozumi Harada	1
3	T cell receptor gene‐modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft‐versus‐host disease 2023 ·Cancer Science ·(unknown), (unknown), Kiyoshi Yasui, Isao Tawara, (unknown), Sachiko Okamoto, Junichi Mineno, Naohiro Seo, Hiroshi Shiku, Susumu Eguchi, Hiroaki Ikeda	6
4	First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors 2020 ·Cancer Immunology Immunotherapy ·Mikiya Ishihara, (unknown), Yoshihiro Miyahara, Daisuke Muraoka, Naozumi Harada, Shinichi Kageyama, Takeshi Sasaki, (unknown), Norihito Soga, Katsunori Uchida, Taizo Shiraishi, Eiichi Sato, Hideki Kanda, Toshiro Mizuno, Gill Webster, Hiroaki Ikeda, Naoyuki Katayama, Yoshiki Sugimura, Hiroshi Shiku	21
5	Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance 2019 ·Journal of Clinical Investigation ·Daisuke Muraoka, Naohiro Seo, Tae Hayashi, Yoshiro Tahara, Keisuke Fujii, Isao Tawara, Yoshihiro Miyahara, (unknown), Hideo Yagita∥, Seiya Imoto, Rui Yamaguchi, Mitsuhiro Komura, Satoru Miyano, Masahiro Goto, Shin‐ichi Sawada, Akira Asai, Hiroaki Ikeda, Kazunari Akiyoshi, Naozumi Harada, Hiroshi Shiku	117
6	Clinical Implications of CD4+CD25+Foxp3+Regulatory T Cell Frequencies After CHP-MAGE-A4 Cancer Vaccination 2018 ·Anticancer Research ·Masataka Wada, Takahiro Tsuchikawa, (unknown), (unknown), (unknown), (unknown), (unknown), Toshiaki Shichinohe, Yoshihiro Miyahara, Shinichi Kageyama, Hiroaki Ikeda, Hiroshi Shiku, Satoshi Hirano	5
7	Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy 2012 ·Cancer Research ·Takuro Noguchi, Takuma Kato, Linan Wang, Yuka Maeda, Hiroaki Ikeda, Eiichi Sato, Alexander Knuth, Sacha Gnjatic, Gerd Ritter, Shimon Sakaguchi, Lloyd J. Old, Hiroshi Shiku, Hiroyoshi Nishikawa	43
8	Improved Expression and Reactivity of Transduced Tumor-Specific TCRs in Human Lymphocytes by Specific Silencing of Endogenous TCR 2009 ·Cancer Research ·Sachiko Okamoto, Junichi Mineno, Hiroaki Ikeda, Hiroshi Fujiwara, Masaki Yasukawa, Hiroshi Shiku, Ikunoshin Kato	143
9	Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432 2009 ·Vaccine ·Masatoshi Aoki, Shugo Ueda, Hiroyoshi Nishikawa, Shigehisa Kitano, (unknown), Hiroaki Ikeda, Hideki Toyoda, Kyosuke Tanaka, Michiyuki Kanai, Arimichi Takabayashi, Hiroshi Imai, Taizo Shiraishi, Eiichi Sato, Hisashi Wada, Eiichi Nakayama, Yoshiyuki Takei, Naoyuki Katayama, Hiroshi Shiku, Shinichi Kageyama	43
10	Line spacing and Legibility in a Local Government Web Site 2007 ·IEICE Technical Report; IEICE Tech. Rep. ·(unknown), (unknown), Hiroaki Ikeda	1
11	Evaluation of a Worksheet for Monitoring Adverse Reactions during Concurrent Chemoradiation 2007 ·Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) ·(unknown), Hiroaki Ikeda, Hisaya Fujiwara, Yuko Kaneyasu, Mayu Yunokawa, Yukari Itakura, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Kenji Kihira	0
12	IFN-γ Controls the Generation/Activation of CD4+CD25+ Regulatory T Cells in Antitumor Immune Response 2005 ·The Journal of Immunology ·Hiroyoshi Nishikawa, Takuma Kato, Isao Tawara, Hiroaki Ikeda, Kagemasa Kuribayashi, Paul M. Allen, Robert D. Schreiber, Lloyd J. Old, Hiroshi Shiku	85
13	Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity 2001 ·Proceedings of the National Academy of Sciences ·Hiroyoshi Nishikawa, (unknown), Hiroaki Ikeda, Miho Sakakura, Yoshihiro Miyahara, (unknown), Katsumi Mukai, Masato Watanabe, Kagemasa Kuribayashi, Lloyd J. Old, Hiroshi Shiku	62
14	IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity breakdown → 2001 ·Nature ·Vijay Shankaran, Hiroaki Ikeda, Allen T. Bruce, J. Michael White, Paul E. Swanson, Lloyd J. Old, Robert D. Schreiber	2060
15	Pharmacokinetics and Adverse Reaction in Methotrexate Therapy of Osteosarcoma. 2000 ·Japanese Journal of Hospital Pharmacy ·Hiroaki Ikeda, Takashi Sugita, (unknown), (unknown), Yasuhiro Kimura, (unknown), (unknown), Yoshikazu Ikuta, Kenji Kihira	1
16	A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. 1998 ·PubMed ·(unknown), Michael Schmitt, Atsunori Hiasa, Yasuhiro Nagata, Hiroaki Ikeda, Yoshihiro Sasaki, Kazunari Akiyoshi, Junzo Sunamoto, Hideo Nakamura, Kagemasa Kuribayashi, Hiroshi Shiku	95
17	Aseptic Preparation and the Clinical Application of Vancomycin Ointment. 1997 ·Japanese Journal of Hospital Pharmacy ·Hiroaki Ikeda, (unknown), (unknown), (unknown), (unknown), (unknown), Kenji Kihira, Hitoshi Kawamoto, Kaoru Kurisu	2
18	A 26-WEEK ORAL REPEATED DOSE TOXICITY STUDY OF (±)-4-DIETHYLAMINO-1, 1-DIMETHYLBUT-2-YN-1-YL 2-CYCLOHEXYL-2-HYDROXY-2-PHENYLACETATE MONOHYDROCHLORIDE MONOHYDRATE (NS-21), A NOVEL DRUG FOR URINARY FREQUENCY AND INCONTINENCE, IN RATS FOLLOWED BY A 9-WEEK RECOVERY TEST 1997 ·The Journal of Toxicological Sciences ·(unknown), (unknown), Hiroaki Ikeda, (unknown), (unknown), Ryoichi Nagata, (unknown), (unknown), (unknown)	4
19	Effect of Age on High-Dose Methotrexate Infusion Therapy. 1996 ·Japanese Journal of Hospital Pharmacy ·Hiroaki Ikeda, Kenji Kihira, (unknown), (unknown), Yasuhiro Kimura, (unknown), (unknown), (unknown), Atsushi Kuramoto	0
20	219 THE EFFECT OF BLOOD COLLECTION ON HEMATOLOGICAL DATA IN CYNOMOLOGUS MONKEYS 1992 ·The Journal of Toxicological Sciences ·(unknown), (unknown), Hiroaki Ikeda, (unknown), Ryoichi Nagata	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact